Early aldosterone blocker for early Conn's syndrome
Treatments studied
Part of Hormones & metabolism clinical trials.
This study tests whether an early treatment (a pill called eplerenone) can help people who have a mild form of a hormone imbalance (primary aldosteronism) that might affect blood pressure or kidney health. It's for people who don't have high blood pressure yet but show early signs of the condition. The study will compare eplerenone to a placebo to see if it helps.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 30 and 55 years old.
- Your weight must be in a certain range (based on body mass index, BMI 18.5 to 35).
- Your blood pressure must be normal or slightly elevated but not high enough for a hypertension diagnosis, and you must not be taking any blood pressure medicines.
- You must have a small nodule on an adrenal gland or slightly enlarged adrenal glands as seen on a CT scan, or the CT must be normal.
- You must meet certain blood test criteria suggesting primary aldosteronism (Conn's syndrome) – your doctor can check this.
- You must not have other causes of high blood pressure or serious kidney, liver, or heart conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how primary aldosteronism affects the heart and blood vessels, and whether blocking its hormone signal (with spironolactone or eplerenone) changes those findings on imaging tests. It is small and focuses on people with confirmed or suspected primary aldosteronism who are being followed for heart health.
This trial tests a new medicine, SAL0140, for people with primary aldosteronism, a condition where the adrenal glands make too much aldosterone, causing high blood pressure. The study aims to see if the drug can lower blood pressure and improve health.
This trial tests whether a treatment called SAAE can improve “ventricular remodeling,” meaning changes in the heart muscle, in people with primary aldosteronism (PA). It may help the heart work more efficiently by targeting the cause of high aldosterone levels.
This trial studies whether a specific treatment (related to spironolactone/aldosterone support) can improve how well your blood vessels work in people with primary aldosteronism. It may help reduce blood pressure risk by improving blood vessel health.
This study examines how different methods of measuring hormone levels in the blood help identify primary aldosteronism (a condition causing high blood pressure). Researchers want to find the best cutoff values to identify patients who might benefit from surgery to remove part of the adrenal gland.
This study tests whether a new pill called baxdrostat can help reduce the activity of aldosterone-producing nodules in the adrenal glands. It uses special imaging to see if the treatment shrinks or changes these nodules, which might help control blood pressure better.
Hear when a new Subclinical Primary Aldosteronism trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.